Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $6,398,000 | -4.7% | 443,702 | 0.0% | 1.52% | -18.8% |
| Q2 2022 | $6,713,000 | +27.4% | 443,702 | 0.0% | 1.86% | +31.8% |
| Q1 2022 | $5,271,000 | -27.2% | 443,702 | -0.6% | 1.42% | +7.3% |
| Q4 2021 | $7,237,000 | -44.0% | 446,457 | -1.4% | 1.32% | -34.2% |
| Q3 2021 | $12,928,000 | +13.4% | 452,970 | +34.3% | 2.00% | +7.0% |
| Q2 2021 | $11,400,000 | +11.8% | 337,291 | 0.0% | 1.87% | +46.1% |
| Q1 2021 | $10,200,000 | -69.5% | 337,291 | -50.0% | 1.28% | -55.5% |
| Q4 2020 | $33,398,000 | +157.9% | 674,582 | +100.0% | 2.88% | -7.6% |
| Q3 2020 | $12,949,000 | -11.1% | 337,291 | 0.0% | 3.12% | -19.5% |
| Q2 2020 | $14,571,000 | +65.5% | 337,291 | 0.0% | 3.87% | -28.0% |
| Q1 2020 | $8,803,000 | -16.5% | 337,291 | 0.0% | 5.38% | +44.0% |
| Q4 2019 | $10,540,000 | – | 337,291 | – | 3.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $1,041,909 | 4.24% |
| Sofinnova Investments, Inc. | 2,194,278 | $11,958,815 | 0.75% |
| DENALI ADVISORS LLC | 85,900 | $468,155 | 0.16% |
| Polar Capital Holdings Plc | 2,103,298 | $11,462,974 | 0.08% |
| Soleus Capital Management, L.P. | 157,182 | $856,642 | 0.08% |
| GSA CAPITAL PARTNERS LLP | 137,299 | $748 | 0.06% |
| Caligan Partners LP | 23,321 | $127,099 | 0.06% |
| Corton Capital Inc. | 12,244 | $66,730 | 0.03% |
| RICE HALL JAMES & ASSOCIATES, LLC | 91,249 | $497,307 | 0.03% |
| CIM INVESTMENT MANAGEMENT INC | 15,313 | $83,456 | 0.03% |